Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 501

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1B
Chunk 501
---

			498,000

			2033

			79,000

			2034

			1,420,000

			2035

			1,611,000

			2036

			1,612,000

			2037

			1,566,000

			2038

			2,573,000

			2039

			1,260,000

			2040

			5,792,000

			2041

			9,172,000

			2042

			15,827,000

			2043

			7,621,000

			2044

			6,188,000

			2044

			7,526,000

			Total

			$
			64,693,000

Share issuance and financing costs will be fully amortized in 2030.

The U.S. non-capital losses carried forward at September 30, 2025 totaled approximately $3.45 million, which do not expire for federal taxes. The U.S. state research and development tax credits carried forward at September 30, 2025 totaled approximately $0.6 million, which do not expire for state taxes. The approximate U.S. state non-capital losses carried forward at September 30, 2025 expire as follows:

			2039

			$
			70,000

			2040

			150,000

			2041

			68,000

			2042

			6,000

			2044

			41,000

			2044

			25,000

			Total

			$
			360,000

10. Financial instruments

(a) Fair values

The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements.

F-22

EDESA BIOTECH, INC.

Notes to Consolidated Financial Statements

For the Years Ended September 30, 2025 and 2024

The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on